Boston Scientific price target raised to $70 from $67 at RBC Capital

RBC Capital raised the firm’s price target on Boston Scientific to $70 from $67 and keeps an Outperform rating on the shares. The company reported a “solid” Q4 earnings beat and also issued “conservative” guidance given its notable product launches, the analyst tells investors in a research note. RBC adds that it remain a buyer at current levels given the room for revenue and EPS revisions higher for Boston Scientific, which the firm sees further justifying the current valuation.